Journal
JNCI CANCER SPECTRUM
Volume 7, Issue 3, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jncics/pkad036
Keywords
-
Categories
Ask authors/readers for more resources
Disparities in the utilization of metastatic renal cell carcinoma systemic therapies were observed among US Medicare beneficiaries from 2015 to 2019, with non-Hispanic Black race and ethnicity and female sex associated with reduced receipt of oral anticancer agents and immunotherapies. These findings highlight the persistence of disparities in mRCC outcomes despite advancements in treatment options.
Disparities in metastatic renal cell carcinoma (mRCC) outcomes persist in the era of oral anticancer agents (OAAs) and immunotherapies (IOs). We examined variation in the utilization of mRCC systemic therapies among US Medicare beneficiaries from 2015 to 2019. Logistic regression models evaluated the association between therapy receipt and demographic covariates including patient race, ethnicity, and sex. In total, 15 407 patients met study criteria. After multivariable adjustment, non-Hispanic Black race and ethnicity was associated with reduced IO (adjusted relative risk ratio [aRRR] = 0.76, 95% confidence interval [CI] = 0.61 to 0.95; P = .015) and OAA receipt (aRRR = 0.76, 95% CI = 0.64 to 0.90; P = .002) compared with non-Hispanic White race and ethnicity. Female sex was associated with reduced IO (aRRR = 0.73, 95% CI = 0.66 to 0.81; P < .001) and OAA receipt (aRRR = 0.74, 95% CI = 0.68 to 0.81; P < .001) compared with male sex. Thus, disparities by race, ethnicity, and sex were observed in mRCC systemic therapy utilization for Medicare beneficiaries from 2015 to 2019.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available